Avantor, Inc. (AVTR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value 0.65%; Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.65% | Share-based compensation / revenue. Period ending 2026-03-31. $42.60M ÷ $6.55B × 100 ≈ 0.65% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 6.55B USD | |
| Stock-based compensation | 42.60M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -294.10M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $6.55B | $42.60M | $-294.10M | (m) | (m) | 0.65% | (m) | (m) |
| 2025-12-31 | (m) | $6.55B | $46.40M | $-246.20M | (m) | (m) | 0.71% | (m) | (m) |
| 2025-09-30 | (m) | $6.58B | $46.20M | $265.50M | (m) | (m) | 0.70% | (m) | (m) |
| 2025-06-30 | (m) | $6.67B | $50.90M | $1.04B | (m) | (m) | 0.76% | (m) | (m) |
| 2025-03-31 | (m) | $6.69B | $46.50M | $1.09B | (m) | (m) | 0.70% | (m) | (m) |
| 2024-12-31 | (m) | $6.78B | $46.80M | $1.08B | (m) | (m) | 0.69% | (m) | (m) |
| 2024-09-30 | (m) | $6.82B | $44.50M | $630.00M | $239.20M | (m) | 0.65% | 2.63× | Reported |
| 2024-06-30 | (m) | $6.83B | $42.40M | $715.60M | $262.90M | (m) | 0.62% | 2.72× | Reported |
| 2024-03-31 | (m) | $6.87B | $40.50M | $611.50M | $275.40M | (m) | 0.59% | 2.22× | Reported |
| 2023-12-31 | (m) | $6.97B | $40.50M | $696.40M | $284.80M | (m) | 0.58% | 2.45× | Reported |
| 2023-09-30 | (m) | $7.04B | $41.70M | $764.90M | $289.30M | (m) | 0.59% | 2.64× | Reported |
| 2023-06-30 | (m) | $7.18B | $44.00M | $830.50M | $284.20M | (m) | 0.61% | 2.92× | Reported |
| 2023-03-31 | (m) | $7.34B | $47.80M | $1.05B | $274.70M | (m) | 0.65% | 3.84× | Reported |
| 2022-12-31 | (m) | $7.51B | $45.80M | $1.13B | $265.80M | (m) | 0.61% | 4.25× | Reported |
| 2022-09-30 | (m) | $7.63B | $49.50M | $1.09B | $256.80M | (m) | 0.65% | 4.25× | Reported |
| 2022-06-30 | (m) | $7.60B | $50.80M | $1.05B | $243.60M | (m) | 0.67% | 4.33× | Reported |
| 2022-03-31 | (m) | $7.55B | $50.00M | $1.01B | $230.70M | (m) | 0.66% | 4.39× | Reported |
| 2021-12-31 | (m) | $7.39B | $50.70M | $972.20M | $217.40M | (m) | 0.69% | 4.47× | Reported |
| 2021-09-30 | (m) | $7.27B | $49.70M | $962.80M | $212.40M | (m) | 0.68% | 4.53× | Reported |
| 2021-06-30 | (m) | $7.04B | $47.70M | $902.80M | $223.50M | (m) | 0.68% | 4.04× | Reported |
| 2021-03-31 | (m) | $6.66B | $47.10M | $814.70M | $264.60M | (m) | 0.71% | 3.08× | Reported |
| 2020-12-31 | (m) | $6.39B | $44.10M | $706.80M | $307.60M | (m) | 0.69% | 2.30× | Reported |
| 2020-09-30 | (m) | $6.13B | $41.90M | $654.10M | $349.80M | (m) | 0.68% | 1.87× | Reported |
| 2020-06-30 | (m) | $6.03B | $32.20M | $620.10M | $382.90M | (m) | 0.53% | 1.62× | Reported |
| 2020-03-31 | (m) | $6.08B | $71.50M | $572.60M | $405.90M | (m) | 1.18% | 1.41× | Reported |
| 2019-12-31 | (m) | $6.04B | $67.90M | $551.80M | $440.00M | (m) | 1.12% | 1.25× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $5.93B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $5.86B | $18.40M | $413.50M | $523.80M | (m) | 0.31% | 0.79× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.25B | $48.20M | $-210.40M | $200.90M | (m) | 3.86% | -1.05× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |